A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (CANOVA) [M13-494]

A Phase3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11; 14) Positive Relapsed or Refractory Multiple Myeloma [M13-494]

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224031

Enrollment

Registered

2018-08-30

Start date

2018-11-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Interventions

investigational material(s) Generic name etc : ABT-199 INN of investigational material : Venetoclax Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Documented diagnosis of multiple myeloma (MM) based on standard IMWG criteria.

Exclusion criteria

Exclusion criteria: History of treatment with venetoclax or another B-Cell Lymphoma (BCL)-2 inhibitor or pomalidomide.

Design outcomes

Primary

Measure	Time frame
efficacy Progression-Free Survival (PFS)	—

Secondary

Measure	Time frame
safety efficacy exploratory pharmacokinetics Very Good Partial Response or Better Response Rate (VGPR) etc.	—

Countries

Asia except Japan, Europe, Japan, North America, Oceania, South America

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026